Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, effectively reduces TD symptoms, but it may also trigger or worsen depressive symptoms by reducing central dopamine and serotonin availability. Here, SLC18A2 is linked to thanatophoric dysplasia.